Tailoring Treatment in FGFR-Positive Advanced Urothelial Cancer

Course Information
Release date: August 2, 2024
Expiration date: November 2, 2024
Estimated time to complete activity: 30 minutes
PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Scientific Affairs, LLC and Seagen, Inc.

PROGRAM OVERVIEW

This case will focus on a 68-year-old man with FGFR3 S249C mutation-positive metastatic urothelial cancer (mUC) and comorbid stage 3b chronic kidney disease (CKD). The discussion will address frontline and subsequent therapies, featuring data from EV-302, CheckMate 901, BLC2001, THOR, NORSE, and FORT-2.

Learning Objectives
TARGET AUDIENCE

This educational activity has been designed to meet the needs of medical and surgical oncologists, urologists, physician assistants, nurse practitioners, nurses, and other healthcare providers involved in treatment and management of patients with genitourinary cancer.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Select personalized treatments for patients with genitourinary malignancies based on disease and patient characteristics
  • Implement biomarker testing in routine clinical practice to guide treatment decisions in the treatment of genitourinary malignancies
Faculty Information and Disclosures
FACULTY
Guru P. Sonpavde, MD
Director of Genitourinary Medical Oncology & Phase I Clinical Research
Christopher K. Glanz Chair for Bladder Cancer Research
AdventHealth Cancer Institute
Professor of Medicine, University of Central Florida
Orlando, Florida
Jonathan Anker, MD, PhD
Clinical and Research Fellow
Department of Hematology and Medical Oncology
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York
DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Guru P. Sonpavde, MD
Advisory Board: Atkis, Bicycle Therapeutics, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Eli Lilly/Loxo Oncology, Gilead, Janssen, Kura Oncology, Merck, MS Pharma, Pfizer, PrecisCa, Scholar Rock, Seattle Genetics/Astellas, Vial
Consultant/Scientific Advisory Board (SAB): Merck, Servier, Syapse, Syncorp
Research Support to Institution: Bristol Myers Squibb, EMD Serono, Jazz Therapeutics
Speaker: Astellas, Aveo, Bayer, Exelixis, Gilead, Janssen, Merck, Natera, Pfizer, Seagen
Writing/Editor Fees: DAVA Oncology, Onviv, Practice Update, UpToDate

Jonathan Anker, MD, PhD does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of August 2, 2024 through November 2, 2024, participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements
MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest